# The Korean powder that stops severe bleeding in one second

> Massive bleeding remains one of the leading causes of preventable death on battlefields, in traffic accidents, and in natural disasters, a problem

- Author: Maxime Marquette
- Publisher: MadMax (https://mad-max.co)
- Section: Investigation
- Published: 2026-07-06
- Canonical URL: https://mad-max.co/en/article/la-poudre-coreenne-qui-arrete-une-hemorragie-grave-en-une-seconde

## Introduction: a discovery that could change emergency medicine

### A problem as old as military medicine

Massive **bleeding** remains one of the leading causes of preventable death on battlefields, in traffic accidents, and in natural disasters, a problem that standard dressings often struggle to solve when a wound is deep, irregular, or hard to reach. A team of South Korean **researchers** says it has developed a radically different solution.

**Scientists** at the **Korea Advanced Institute of Science and Technology**, better known by the acronym **KAIST**, have developed a **hemostatic** spray **powder** capable of forming a powerful **gel** barrier in roughly **one second** after being applied to a wound (Medical Xpress).

### A multidisciplinary team, including an active-duty officer

The project was jointly led by **professor Steve Park**, of the department of materials science and engineering, and **professor Sangyong Jon**, of the department of biological sciences, with the notable involvement of an active-duty major in the South Korean army as part of the **research** team (WION). This makeup reflects the project's explicitly military ambition from the outset.

The **results** of this **research** were published in the **scientific** journal **Advanced Functional Materials**, a mark of rigor since the study went through peer review before its official **publication** on December 29, 2025 (informat.ro).

*I find it remarkable that such a promising innovation comes from direct collaboration between civilian and military researchers. It illustrates just how much real needs on the ground, especially military ones, can accelerate advances that will later benefit the entire civilian population.*

## How this powder, called AGCL, works

### Clever chemistry built on natural materials

The **powder**, named **AGCL**, combines three biocompatible components: **alginate** and **gellan gum**, which react with the calcium present in blood to quickly form a **gel**, along with **chitosan**, which binds to blood components to reinforce chemical and biological hemostasis (Medical Xpress). This combination allows for both a physical and a chemical action on the wound.

On contact with cations such as calcium present in blood, the **powder** turns into a **gel** state within one second, instantly sealing the wound. This chemical reaction, called ionic gelation, does not turn the entire blood supply into gel, but instead creates a localized barrier right at the wound site (fact-check published on social media).

### Impressive absorption capacity

Thanks to an internal three-dimensional structure, this **powder** can absorb up to **seven times its own weight** in blood, roughly **725%**, which allows it to quickly stop blood flow even in cases of excessive, high-pressure bleeding (Medical Xpress). This performance far exceeds that of **hemostatic** agents currently available commercially.

The resulting **gel** also shows an adhesive strength above **40 kilopascals**, a pressure level sufficient to withstand firm manual pressure, an essential technical criterion for field use in often chaotic conditions (Medical Xpress).

*I'm impressed by this absorption capacity, which exceeds seven times the powder's own weight. But I stay alert to the crucial distinction between effective localized gelation and the exaggerated claim that the entire bloodstream turns to gel, a simplification already circulating widely online.*

## Encouraging results in animal trials

### A measurable reduction in blood loss

In surgical trials involving liver injuries, the **AGCL** **powder** significantly reduced blood loss and shortened the time needed to stop the **bleeding**, compared with existing commercial **hemostatic** agents already used in clinical settings (WION). Liver function in the tested subjects returned to normal within two weeks of the surgical procedure.

No signs of systemic toxicity were detected during these trials, an encouraging result for the technology's continued development ahead of possible **clinical trials** on human subjects (WION).

### A safety profile that reassures researchers

Lab tests revealed a hemolysis rate below **3%**, cell viability above **99%**, and antibacterial efficacy reaching **99.9%**, figures that suggest a solid safety profile for this new generation of **hemostatic** agent (WION). These preliminary **results** will still need to be confirmed through rigorous **clinical trials** before any widespread use in humans.

The **powder** also retains its effectiveness for roughly two years at room temperature, with no refrigeration required, a major logistical advantage for rapid deployment on military operational theaters or in remote disaster zones (informat.ro).

*I see this two-year shelf life without refrigeration as one of the most promising aspects of this discovery. An emergency medical solution that doesn't depend on a cold chain could literally save lives in isolated regions where access to care remains extremely limited.*

## Intended applications, from the battlefield to the emergency room

### A stated priority for the military context

The **research** team explicitly designed this technology to improve the survival odds of wounded combatants, a focus reinforced by the presence of an active-duty service member within the research project itself. The goal is to give military doctors and first responders a faster, more reliable tool than traditional compression and dressing methods (WION).

On a **battlefield**, every second saved in controlling **bleeding** can mean the difference between life and death, particularly when medical evacuation can take time in active conflict zones such as those seen in **Ukraine** in recent years.

### An equally significant civilian potential

Beyond the military context, **researchers** envision applications in civilian emergency medicine, notably for paramedics, hospital emergency services, and potentially, eventually, first-aid kits for the general public (New York Post). This versatility could democratize effective control of severe **bleeding** well beyond strictly military settings.

The ease of use, summed up by the **researchers** themselves as **aim, spray, seal**, could allow minimally trained responders to correctly apply the **treatment** in high-stress emergency situations.

*I see in this dual application, military and civilian, a rare opportunity to turn a defense innovation into tangible benefit for the general population. This is exactly the kind of technological spillover the West should value and fund more.*

## What this means for first responders

### A potentially decisive time saving

For first responders, whether military doctors, paramedics, or volunteer rescuers, the ease of applying this **powder** could considerably reduce the time needed to stabilize a victim before transport to a specialized medical facility. Unlike traditional compression dressings, which often require several minutes of sustained application, this technology promises near-instant action.

This speed of action could prove especially valuable in mass-casualty triage situations, such as terrorist attacks, natural disasters, or armed conflicts involving large numbers of simultaneous casualties, where every minute saved per patient can literally save additional lives.

### Minimal training required for effective use

One of the most compelling arguments in favor of this technology lies in its ease of use, which does not require extensive medical training to apply correctly, unlike certain suturing or specialized compression techniques that demand significant clinical expertise.

This accessibility could democratize the control of severe **bleeding**, particularly in regions where access to qualified medical personnel remains limited, a public health issue especially relevant in rural areas or prolonged conflict settings.

*I see real democratizing potential for emergency care in this ease of use. A technology that doesn't require years of medical training to save a life is exactly the kind of innovation emergency medicine should prioritize worldwide.*

## The limits and questions that remain open

### No confirmed commercialization date

Despite the enthusiasm sparked by this **discovery**, the **research** organization has not yet revealed a precise timeline for the commercial availability of this **hemostatic** **powder**, leaving uncertainty about how long it will take before it becomes accessible to healthcare professionals or the general public (New York Post).

The move from animal trials to **clinical trials** on human subjects is generally a long and costly step, subject to strict regulatory requirements that can take several years to reach official approval.

### Scientific precedents that call for caution

Other innovative **hemostatic** agents, developed by **research** teams around the world and published in journals indexed on **PubMed**, have also shown promising laboratory **results** without necessarily translating into widespread clinical adoption, a useful reminder that laboratory innovation does not automatically guarantee large-scale commercial or medical success.

The **researchers** themselves acknowledge that further trials will be needed to confirm the safety and effectiveness of this technology under real clinical conditions, beyond the controlled environments of the animal trials conducted so far.

*I'd rather temper the media enthusiasm surrounding this discovery with a dose of scientific realism. The history of medical innovation is littered with promising laboratory results that never reached a patient's bedside. Hope is legitimate, but so is caution.*

## Reactions from the international medical community

### A generally positive but cautious reception

Several emergency medicine experts, cited in various international reports since the initial **publication**, praise the originality of the chemical approach used by the **KAIST** team, while noting that the path from animal trials to human clinical application remains fraught with considerable regulatory and **scientific** hurdles.

This measured reception reflects a healthy **scientific** culture, where enthusiasm for a promising **discovery** must never eclipse the need to rigorously validate every step before widespread clinical adoption worldwide.

### Growing interest from Western armed forces

Specialized publications in military medicine have also noted this Korean breakthrough, suggesting that Western armies could eventually take an interest in equipping their own combat medical units, provided **clinical trials** confirm the safety and effectiveness observed in preliminary animal trials.

This potential military interest underscores the strategic importance of this kind of medical innovation, which extends well beyond a strictly **scientific** framework to touch on national security considerations and preparedness for future conflicts.

*I believe the interest shown by Western armed forces in this Korean technology illustrates well the growing interdependence among democratic allies when it comes to military medical innovation. This kind of international collaboration, when properly managed, strengthens the collective security of the entire free world.*

## The broader context of South Korean medical innovation

### A healthcare industry in full expansion

**South Korea** has been investing heavily in biomedical **research** for several years, positioning institutions like **KAIST** among the world's reference centers for innovation in materials science applied to health. This **discovery** fits into a broader trajectory of Korean technological breakthroughs gaining growing international recognition.

The funding behind this **research**, combining academic expertise with direct military interest, also illustrates a collaboration model that could inspire other Western countries looking to accelerate the transfer of technology from the lab to the operational field.

### An increasingly fierce international competition

Several research teams around the world, notably in the United States and Europe, are also working on next-generation **hemostatic** agents, often inspired by similar biological **mechanisms** involving natural polymers and rapid gelation reactions. This international **scientific** competition ultimately benefits patients, by accelerating the pace of **discoveries**.

**Publication** in an internationally recognized peer-reviewed journal also allows other **research** teams to verify, reproduce, and potentially improve this technology, an essential **scientific** process before any widespread clinical adoption.

*I believe this global scientific competition around hemostatic agents should be actively encouraged by Western governments. Every advance, regardless of its country of origin, ends up benefiting humanity as a whole when research stays open and verifiable.*

## Conclusion: a promising advance that still has to prove itself

### What this discovery really represents

The **hemostatic** powder developed by **researchers** at **KAIST** represents a real and well-documented technical advance in controlling severe **bleeding**, with solid preliminary **data** on its effectiveness and safety in an experimental animal setting. Its ability to act within one second on deep, irregular wounds fills a therapeutic gap long recognized by the emergency medical community.

This innovation also illustrates the value of Korean **scientific** **research** in the biomedical field, a sector where international competition, notably with Western and Chinese labs, is intensifying rapidly.

### The road still ahead before widespread use

Before this technology can concretely save lives on battlefields or in emergency rooms, it will need to pass through the rigorous stages of human **clinical trials**, obtain the necessary regulatory approvals, and prove its viability under large-scale industrial production conditions.

It would be premature to promise an immediate revolution in emergency medicine, but this **discovery** certainly deserves close monitoring by the international **scientific** and medical community in the months and years ahead.

*I'll close this investigation with measured hope, neither naive nor cynical. This Korean powder could one day save lives on battlefields and in civilian emergency rooms, but only the rigor of clinical trials to come will turn this promise into verifiable reality.*

**By Maxime Marquette, columnist**

## Columnist's transparency note

### Editorial stance

I am not a journalist but a **columnist and analyst**. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies.

I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. **I claim analytical clarity**, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events.

### Method and sources

This text keeps the basic distinction between **verified facts and interpretive analysis**. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under **Sources**, never here.

**Primary source families** used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies.

**Secondary source families**: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations.

When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under **Sources**.

### Nature of the analysis

The analyses, interpretations and perspectives in the analytical sections of this article are a **critical, contextual synthesis** based on the information available, the trends observed and the expert comments cited in the sources consulted.

My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors.

This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text.

## Sources

### Primary sources

- Medical Xpress — New sprayable powder forms instant gel barrier to stop severe bleeding, December 29, 2025

- informat.ro — New hemostatic agent developed for the rapid cessation of severe hemorrhages, January 6, 2026

### Secondary sources

- New York Post — South Korean scientists create life-saving spray to stop bleeding instantly, February 7, 2026

- WION Podcast — A spray powder stops bleeding in one second, January 24, 2026

- Fossbytes — Fact-check on the KAIST discovery

- DBR — A KAIST major contributes to development of instant hemostatic spray, December 29, 2025

---

Source: Maxime Marquette, MadMax. When citing, name the author and link https://mad-max.co/en/article/la-poudre-coreenne-qui-arrete-une-hemorragie-grave-en-une-seconde